DOCSLIB.ORG

Benzodiazepines and GHB Detection and Pharmacology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Benzodiazepines and GHB Detection and Pharmacology Benzodiazepines and GHB Detection and Pharmacology Edited by Salvatore J. Salamone Humana Press Benzodiazepines and GHB FORENSIC SCIENCE- AND- MEDICINE Steven B. Karch, MD, SERIES EDITOR BUPRENORPHINE THERAPY OF OPIATE ADDICTION, edited by PASCAL KINTZ AND PIERRE MARQUET, 2002 ON-SITE DRUG TESTING, edited by AMANDA J. JENKINS AND BRUCE A. GOLDBERGER, 2001 BENZODIAZEPINES AND GHB: DETECTION AND PHARMACOLOGY, edited by Salvatore J. Salamone, 2001 TOXICOLOGY AND CLINICAL PHARMACOLOGY OF HERBAL PRODUCTS, edited by Melanie Johns Cupp, 2000 CRIMINAL POISONING: INVESTIGATIONAL GUIDE FOR LAW ENFORCEMENT, TOXICOLOGISTS, FORENSIC SCIENTISTS, AND ATTORNEYS, by John H. Trestrail, III, 2000 A PHYSICIAN'S GUIDE TO CLINICAL FORENSIC MEDICINE, edited by Margaret M. Stark, 2000 BENZODIAZEPINES AND GHB Detection and Pharmacology Edited by Salvatore J. Salamone, PhD Roche Diagnostics Corp. Indianapolis, IN Humana Press Totowa, New Jersey To my children Katherine, Norah, and Hannah © 2001 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. The content and opinions expressed in this book are the sole work of the authors and editors, who have warranted due diligence in the creation and issuance of their work. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences arising from the information or opinions presented in this book and make no warranty, express or implied, with respect to its contents. This publication is printed on acid-free paper. ∞ ANSI Z39.48-1984 (American Standards Institute) Permanence of Paper for Printed Library Materials. Cover design by Patricia F. Cleary. For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel: 973-256-1699; Fax: 973-256-8341; E-mail: [email protected], or visit our Website at www.humanapress.com Photocopy Authorization Policy: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US $10.00 per copy, plus US $00.25 per page, is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [0-89603-981-1/01 $10.00 + $00.25]. Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1 Library of Congress Cataloging in Publication Data Benzodiazepines and GHB: detection and pharmacology p. ; cm. -- (Forensic science and medicine) Includes bibliographical references and index. ISBN 0-89603-981-1 (alk. paper) 1. Benzodiazepines--Analysis. 2. Gamma-hydroxybutyrate--Analysis. 3. Forensic pharmacology. I. Salamone, Salvatore J. II. Series. [DNLM: 1. Body Fluids--chemistry. 2. Forensic Medicine--methods. 3. Benzodiazepines--isolation & purification. 4. Benzodiazepines--metabolism. 5. Benzodiazepines--pharmacology. 6. Hair--chemistry. 7. Hydroxybutyrates--isolation & purification. 8. Hydroxybutyrates--metabolism. 9. Hydroxybutyrates-- pharmacology. W 750 D4799 2001] RA1242.B43 D48 2001 614'.1--dc21 2001024305 Preface Since the first benzodiazepines were introduced to the market in 1960, there has been an evolution of these drugs toward lower dosage, shorter action, and faster clearance. As a consequence, this new generation of benzodiaz- epines eluded detection in many laboratories. Benzodiazepines can be abused in several different ways. These drugs are often given in conjunction with alcohol to enhance the desired effect, thus requiring lower doses. This situation has created added challenges to the toxicologist. Use of normal screening and confirmation methods may not detect the lower levels of these drugs, and in some cases the laboratory may not have capability in the methodologies to detect a particular drug. Another recent challenge for the toxicologist is the detection of γ-hydroxy- butyric acid (GHB). The use of this drug is widespread and it is easily obtained or prepared in clandestine laboratories. Similar to the low-dosed benzodiazepines (LDBs) the effect is also potentiated by alcohol. Its detection is difficult owing to the rapid clearance and the low concentrations that appear in urine or serum. Detection methods for GHB are not common, but labora- tories are now developing new methods as its popularity is highlighted. The purpose of Benzodiazepines and GHB: Detection and Pharmacology is to provide some background on the pharmacology and metabolism of LDB and GHB and to help the toxicologist develop methodologies that will enable better detection of these drugs in various body fluids, as well as in hair. The first chapter provides background on the LDBs by dealing with the pharmacol- ogy and metabolism of these drugs. Chapter 2 deals with immunoassay detection of LDBs, reviewing the current state of testing and providing methodologies that will increase the sensitivity of immunoassay reagents. Chapters 3 and 4 focus on methods for the detection of Rohypnol® and other LDBs by mass spectrometry. Chapter 5 addresses the detection of benzodiazepines in hair. Chapter 6 addresses the pharmacology and detection of GHB, and finally v vi Preface Chapter 7 presents a case study examining the prevalence of drugs used in cases of alleged sexual assault. Benzodiazepines and GHB: Detection and Pharmacology would not have been possible without the cooperation of all the authors. I wish to thank each of them for their efforts. I would like to thank Dr. Stephen Karch and Humana Press for the opportunity to be involved with such an endeavor. Salvatore J. Salamone, PhD Contents Preface .................................................................................................... v Contributors .......................................................................................... xi CHAPTER 1 Pharmacology of Flunitrazepam and Other Benzodiazepines Rudolf Brenneisen and Lionel Raymond ................................................. 1 1. Introduction .......................................................................................................... 1 2. Chemistry ............................................................................................................. 2 3. Pharmacokinetics ................................................................................................. 4 3.1. Absorption, Distribution, and Plasma Levels ............................................. 4 3.2. Half-Life vs Duration of Action .................................................................. 7 3.3. Metabolism and Excretion........................................................................... 7 4. Pharmacodynamics .............................................................................................. 8 4.1. Sites of Action.............................................................................................. 8 4.2. Acute Effect ............................................................................................... 10 4.3. Chronic Administration and Abuse Liability ........................................... 11 4.4. Pharmacokinetics vs Pharmacodynamics ................................................. 12 4.5. Rohypnol®: The Debate ............................................................................ 13 References .............................................................................................................. 14 vii viii Contents CHAPTER 2 Immunoassay Detection of Benzodiazepines Tamara N. St. Claire and Salvatore J. Salamone ...................................17 1. Introduction ........................................................................................................ 17 2. Optimal Enzyme Activity .................................................................................. 19 2.1. Conditions .................................................................................................. 19 2.2. Activity ....................................................................................................... 20 3. Cutoff ................................................................................................................. 22 4. Immunoassays .................................................................................................... 22 5. Methods .............................................................................................................. 28 5.1. Manual β-Glucuronidase Treatment ......................................................... 28 5.2. Automated β-Glucuronidase Treatment ................................................... 28 5.2.1. Online with the Hitachi 717............................................................ 28 5.2.2. Online with the COBAS INTEGRA 700 ....................................... 29 5.2.3. A General Scheme........................................................................... 29 6. Conclusion ......................................................................................................... 29 References .............................................................................................................
Load more

Recommended publications
  • Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW
    Guideline Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW Summary To provide the most up-to-date knowledge and current level of best practice for the treatment of withdrawal from alcohol and other drugs such as heroin, and other opioids, benzodiazepines, cannabis and psychostimulants. Document type Guideline Document number GL2008_011 Publication date 04 July 2008 Author branch Centre for Alcohol and Other Drugs Branch contact (02) 9424 5938 Review date 18 April 2018 Policy manual Not applicable File number 04/2766 Previous reference N/A Status Active Functional group Clinical/Patient Services - Pharmaceutical, Medical Treatment Population Health - Pharmaceutical Applies to Area Health Services/Chief Executive Governed Statutory Health Corporation, Board Governed Statutory Health Corporations, Affiliated Health Organisations, Affiliated Health Organisations - Declared Distributed to Public Health System, Ministry of Health, Public Hospitals Audience All groups of health care workers;particularly prescribers of opioid treatments Secretary, NSW Health Guideline Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ space space Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW space Document Number GL2008_011 Publication date 04-Jul-2008 Functional Sub group Clinical/ Patient Services - Pharmaceutical Clinical/ Patient Services - Medical Treatment Population Health - Pharmaceutical
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Risk Based Requirements for Medicines Handling
    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
    [Show full text]
  • Analytical Methods for Determination of Benzodiazepines. a Short Review
    Cent. Eur. J. Chem. • 12(10) • 2014 • 994-1007 DOI: 10.2478/s11532-014-0551-1 Central European Journal of Chemistry Analytical methods for determination of benzodiazepines. A short review Review Article Paulina Szatkowska1, Marcin Koba1*, Piotr Kośliński1, Jacek Wandas1, Tomasz Bączek2,3 1Department of Toxicology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland 3Institute of Health Sciences, Division of Human Anatomy and Physiology, Pomeranian University of Słupsk, 76-200 Słupsk, Poland Received 16 July 2013; Accepted 6 February 2014 Abstract: Benzodiazepines (BDZs) are generally commonly used as anxiolytic and/or hypnotic drugs as a ligand of the GABAA-benzodiazepine receptor. Moreover, some of benzodiazepines are widely used as an anti-depressive and sedative drugs, and also as anti-epileptic drugs and in some cases can be useful as an adjunct treatment in refractory epilepsies or anti-alcoholic therapy. High-performance liquid chromatography (HPLC) methods, thin-layer chromatography (TLC) methods, gas chromatography (GC) methods, capillary electrophoresis (CE) methods and some of spectrophotometric and spectrofluorometric methods were developed and have been extensively applied to the analysis of number of benzodiazepine derivative drugs (BDZs) providing reliable and accurate results. The available chemical methods for the determination of BDZs in biological materials and pharmaceutical formulations are reviewed in this work. Keywords: Analytical methods • Benzodiazepines • Drugs analysis • Pharmaceutical formulations © Versita Sp. z o.o. 1. Introduction and long). For this reason, an application of these drugs became broader allowing their utility to a larger extent, Benzodiazepines have been first introduced into medical and at the same time, problems related to drug abuse practice in the 60s of the last century.
    [Show full text]
  • The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe
    EMBARGO — 7 JUNE 7. 6. 2018 UPDATED 11:30 Central European Time/CET (10:30 Western European Time/WET/Lisbon) Proof - 28 May 2018 not for circulation PERSPECTIVES ON DRUGS The misuse of benzodiazepines among high-risk opioid users in Europe Benzodiazepines are a widely prescribed I Introduction group of medicines with a range of clinical uses that include treating Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. anxiety, insomnia and managing alcohol They are useful in the short-term treatment of anxiety and withdrawal. This group of medicines is insomnia, and in managing alcohol withdrawal (Medicines often misused by high-risk opioid users, and Healthcare Products Regulatory Agency, 2015). Like all medicines, benzodiazepines can produce side effects. They and this is associated with considerable may also be misused, which we define as use without a morbidity and mortality. This paper prescription from a medical practitioner or, if prescribed, when describes the impact of benzodiazepines they are used outside accepted medical practice or guidelines. misuse on the health and treatment of While the misuse of benzodiazepines has been identified high-risk opioid users. as a concern for large groups in the general population, for example, among elderly people and women, this analysis focuses specifically on misuse among high-risk opioid users (1), a group of people among whom these medicines have been linked with severe treatment challenges and implicated in considerable numbers of drug-related deaths. It is important to stress that much benzodiazepine prescribing to high-risk drug users is done with legitimate therapeutic aims in mind.
    [Show full text]
  • Pharmacological Properties of GABAA- Receptors Containing Gamma1
    Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 Molecular PharmacologyThis article hasFast not Forward.been copyedited Published and formatted. on The November final version 7, may 2005 differ as from doi:10.1124/mol.105.017236 this version. MOLPHARM/2005/017236 Pharmacological properties of GABAA- receptors containing gamma1- subunits Khom S.1, Baburin I.1, Timin EN, Hohaus A., Sieghart W., Hering S. Downloaded from Department of Pharmacology and Toxicology, University of Vienna Center of Brain Research , Medical University of Vienna, Division of Biochemistry and molpharm.aspetjournals.org Molecular Biology at ASPET Journals on September 27, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Running Title: GABAA- receptors containing gamma1- subunits Corresponding author: Steffen Hering Department of Pharmacology and Toxicology University of Vienna Althanstrasse 14 Downloaded from A-1090 Vienna Telephone number: +43-1-4277-55301 Fax number: +43-1-4277-9553 molpharm.aspetjournals.org [email protected] Text pages: 29 at ASPET Journals on September 27, 2021 Tables: 2 Figures: 7 References: 26 Abstract: 236 words Introduction:575 words Discussion:1383 words 2 Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Abstract GABAA receptors composed of α1, β2, γ1-subunits are expressed in only a few areas of the brain and thus represent interesting drug targets.
    [Show full text]
  • Hsrs Alcohol and Other Drug Abuse Module
    WORKER ID (Field 1) OPTIONAL DEFINITION: The primary worker assigned to the client, or the person designated by the agency as having overall responsibility for the client or case. This is the person who will get information back about the client if any is requested. You may use a provider ID if you have delegated overall responsibility to a provider and you want them to get back all information about this client. PURPOSE: For local use to connect reports to specific case managers. MA NUMBER (Field 2) REQUIRED IF MEDICAL ASSISTANCE RECIPIENT CODES: Enter the client’s 10 digit MA Number. PURPOSE: For comparison with other databases (Medical Assistance; DWD employment data; Crime Information Bureau, etc.) CLIENT ID (Field 3) REQUIRED, COMPUTER GENERATED DEFINITION: An identifier that is computer generated for each individual reported on HSRS. Full legal name, birthdate, and sex are used to produce a 14 character ID which bears no resemblance to the client’s name. ENTER: May be left blank if name, birthdate, and sex are reported. OR Enter the 14 character HSRS client identification number. The ID will be generated and returned to you on the terminal screen. Copy it down or print the screen. Once the ID number is generated, use it on all future input. PURPOSE: To maintain client confidentiality while allowing reports to be produced on individual clients for audit purposes; to produce reports on multiple services to the same individual; to produce client number listings for recidivist clients. AODA - 1 NAME - LAST, FIRST, MIDDLE, SUFFIX (Fields 4a-d) REQUIRED TO GENERATE ID (THEN OPTIONAL) DEFINITION: The full legal name of the client.
    [Show full text]
  • Introduction the Abuse of Psychotropic Substances Causes
    Investigation of the Reporting System of Schedule-4 Psychotropic Substances in Thailand: A Case Study of Pinazepam นิพนธ์ต้นฉบ ับ Original Article กนกวรรณ โสภากิติบูรณ์1* และ เยาวลักษณ์ อ ่าร าไพ2 Kanokwan Sopakitiboon1* and Yaowalak Amrumpai2 1 กลุ่มก ากับดูแลหลังออกสูต่ ลาด กองควบคุมวัตถุเสพติด ส านักงานคณะกรรมการอาหารและยา 1 Post-marketing Control Unit, Narcotics Control Division, Thai Food and Drug จังหวัดนนทบุรี 1000 Administration, Nonthaburi Province, Thailand, 11000 2 ภาควชิ าเภสชั กรรมชมุ ชน คณะเภสชั ศาสตร ์ มหาวทิ ยาลยั ศลิ ปากร นครปฐม 73000 2 Department of Community Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand, 73000 * ติดต่อผู้นิพนธ์: [email protected] * Corresponding author: [email protected] วารสารไทยเภสชั ศาสตรแ์ ละวทิ ยาการสุขภาพ 2560;12(3):138-146. Thai Pharmaceutical and Health Science Journal 2017;12(3):138-146. บทค ัดย่อ Abstract วัตถุประสงค์: การรั่วไหลของวตั ถุออกฤทธใิ์ นประเภท 4 ออกนอกระบบควบคุม Objectives: The leakage of schedule-4 psychotropic substances from the การกระจายยาเป็นปญั หาที่ส าคัญมากแต่ยังไม่มีการวิเคราะห์อย่างชัดเจน formal distribution channel is a crucial problem but still unexplored. This การศึกษานี้จึงมุ่งตรวจสอบระบบรายงานและการสอบทานข้อมูลการซื้อ-ขายวัตถุ study aimed to investigate the reporting system of the substances using ออกฤทธฯิ์ โดยใช้พินาซีแพมเป็นกรณีศึกษา วิธีการศึกษา: เป็นการศึกษาแบบ pinazepam as a study drug. Method: In this cross-sectional study, we ภาคตัดขวางที่ใช้การตรวจสอบรายงานแบบเอกสารและแบบออนไลน์ของพินาซี investigated the reports both
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Drug Screening: Actual Status, Pitfalls and Suggestions for Improvement Drogenscreening: Gegenwa¨ Rtiger Stand, Fehlermo¨ Glichkeiten Und Verbesserungsvorschla¨Ge
    J Lab Med 2004;28(4):317–325 ᮊ 2004 by Walter de Gruyter • Berlin • New York 2004/03304 Drug Monitoring und Toxikologie Redaktion: V. W. Armstrong Drug screening: Actual status, pitfalls and suggestions for improvement Drogenscreening: Gegenwa¨ rtiger Stand, Fehlermo¨ glichkeiten und Verbesserungsvorschla¨ge Wolf R. Ku¨ lpmann* pretierbar. In Wirklichkeit mu¨ ssen viele Aspekte beru¨ ck- sichtigt werden, um einen aussagekra¨ ftigen Befund zu Klinische Chemie, Medizinische Hochschule Hannover, erhalten, z.B. Pra¨ analytik, Spezifita¨ t und Empfindlichkeit Hannover, Germany des Verfahrens oder Qualita¨ tssicherung. Obwohl die Abstract mechanisierten Meßverfahren naturgema¨ ß quantitative Ergebnisse liefern, wird aufgezeigt, daß es sich in der Immunoassays for drug screening are often regarded as Regel empfiehlt, qualitative Befunde zu erstellen. Die procedures which are easily performed and interpreted. Verfahren erlauben aber im Gegensatz zu den auch fu¨r But in fact, many aspects have to be considered to diese Zwecke verwendeten Teststreifen die Entschei- obtain a meaningful result. Among these are sampling, dungsgrenze (cut-off) der jeweiligen Fragestellung anzu- specificity and sensitivity of assays, and quality assess- passen, z.B. bei akuter Intoxikation, chronischem Abusus ment. Although the mechanised procedures yield quan- oder U¨ berwachung des Drogenentzugs. titative results, there are good reasons to generally report Ein schwerwiegender Nachteil von Immunoassays zum qualitative findings. The mechanised procedures allow Nachweis von Amphetamin und a¨ hnlichen Substanzen, the adjustment of the cut-off concentration to the clinical Barbituraten, Benzodiazepinen und Opiaten besteht dar- setting, e.g. in the case of acute intoxication, chronic in, daß eine starke Kreuzreaktivita¨ t des Antiko¨ rpers abuse or drug withdrawal, an important advantage as gegenu¨ ber pharmakologisch wenig wirksamen Verbin- compared to test strips.
    [Show full text]